345 related articles for article (PubMed ID: 27111637)
1. Aberrant bispecific antibody pharmacokinetics linked to liver sinusoidal endothelium clearance mechanism in cynomolgus monkeys.
Datta-Mannan A; Croy JE; Schirtzinger L; Torgerson S; Breyer M; Wroblewski VJ
MAbs; 2016 Jul; 8(5):969-82. PubMed ID: 27111637
[TBL] [Abstract][Full Text] [Related]
2. Modulation of the Biophysical Properties of Bifunctional Antibodies as a Strategy for Mitigating Poor Pharmacokinetics.
Datta-Mannan A; Brown RM; Fitchett J; Heng AR; Balasubramaniam D; Pereira J; Croy JE
Biochemistry; 2019 Jul; 58(28):3116-3132. PubMed ID: 31241304
[TBL] [Abstract][Full Text] [Related]
3. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic Developability and Disposition Profiles of Bispecific Antibodies: A Case Study with Two Molecules.
Datta-Mannan A; Brown R; Key S; Cain P; Feng Y
Antibodies (Basel); 2021 Dec; 11(1):. PubMed ID: 35076469
[TBL] [Abstract][Full Text] [Related]
5. The interplay of non-specific binding, target-mediated clearance and FcRn interactions on the pharmacokinetics of humanized antibodies.
Datta-Mannan A; Lu J; Witcher DR; Leung D; Tang Y; Wroblewski VJ
MAbs; 2015; 7(6):1084-93. PubMed ID: 26337808
[TBL] [Abstract][Full Text] [Related]
6. Nanocell targeting using engineered bispecific antibodies.
Taylor K; Howard CB; Jones ML; Sedliarou I; MacDiarmid J; Brahmbhatt H; Munro TP; Mahler SM
MAbs; 2015; 7(1):53-65. PubMed ID: 25523746
[TBL] [Abstract][Full Text] [Related]
7. Exploring molecular determinants and pharmacokinetic properties of IgG1-scFv bispecific antibodies.
Aertker KMJ; Pilvankar MR; Prass TM; Blech M; Higel F; Kasturirangan S
MAbs; 2024; 16(1):2318817. PubMed ID: 38444390
[TBL] [Abstract][Full Text] [Related]
8. Fab-based bispecific antibody formats with robust biophysical properties and biological activity.
Wu X; Sereno AJ; Huang F; Lewis SM; Lieu RL; Weldon C; Torres C; Fine C; Batt MA; Fitchett JR; Glasebrook AL; Kuhlman B; Demarest SJ
MAbs; 2015; 7(3):470-82. PubMed ID: 25774965
[TBL] [Abstract][Full Text] [Related]
9. Toward in vitro-to-in vivo translation of monoclonal antibody pharmacokinetics: Application of a neonatal Fc receptor-mediated transcytosis assay to understand the interplaying clearance mechanisms.
Jaramillo CAC; Belli S; Cascais AC; Dudal S; Edelmann MR; Haak M; Brun ME; Otteneder MB; Ullah M; Funk C; Schuler F; Simon S
MAbs; 2017 Jul; 9(5):781-791. PubMed ID: 28440708
[TBL] [Abstract][Full Text] [Related]
10. Engineered FcRn Binding Fusion Peptides Significantly Enhance the Half-Life of a Fab Domain in Cynomolgus Monkeys.
Datta-Mannan A; Boyles J; Huang L; Jin ZY; Peariso A; Murphy AT; Ellis B; Douglass N; Norouziyan-Cooper F; Witcher DR
Biotechnol J; 2019 Mar; 14(3):e1800007. PubMed ID: 29802766
[TBL] [Abstract][Full Text] [Related]
11. Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration.
Smith B; Kiessling A; Lledo-Garcia R; Dixon KL; Christodoulou L; Catley MC; Atherfold P; D'Hooghe LE; Finney H; Greenslade K; Hailu H; Kevorkian L; Lightwood D; Meier C; Munro R; Qureshi O; Sarkar K; Shaw SP; Tewari R; Turner A; Tyson K; West S; Shaw S; Brennan FR
MAbs; 2018 Oct; 10(7):1111-1130. PubMed ID: 30130439
[TBL] [Abstract][Full Text] [Related]
12. FcRn affinity-pharmacokinetic relationship of five human IgG4 antibodies engineered for improved in vitro FcRn binding properties in cynomolgus monkeys.
Datta-Mannan A; Chow CK; Dickinson C; Driver D; Lu J; Witcher DR; Wroblewski VJ
Drug Metab Dispos; 2012 Aug; 40(8):1545-55. PubMed ID: 22584253
[TBL] [Abstract][Full Text] [Related]
13. Modification of the Fc Region of a Human Anti-oncostatin M Monoclonal Antibody for Higher Affinity to FcRn Receptor and Extension of Half-life in Cynomolgus Monkeys.
Nnane IP; Han C; Jiao Q; Tam SH; Davis HM; Xu Z
Basic Clin Pharmacol Toxicol; 2017 Jul; 121(1):13-21. PubMed ID: 28132416
[TBL] [Abstract][Full Text] [Related]
14. Modulation of protein A binding allows single-step purification of mouse bispecific antibodies that retain FcRn binding.
Zwolak A; Armstrong AA; Tam SH; Pardinas JR; Goulet DR; Zheng S; Brosnan K; Emmell E; Luo J; Gilliland GL; Chiu ML
MAbs; 2017; 9(8):1306-1316. PubMed ID: 28898162
[TBL] [Abstract][Full Text] [Related]
15. Computational design of a specific heavy chain/κ light chain interface for expressing fully IgG bispecific antibodies.
Froning KJ; Leaver-Fay A; Wu X; Phan S; Gao L; Huang F; Pustilnik A; Bacica M; Houlihan K; Chai Q; Fitchett JR; Hendle J; Kuhlman B; Demarest SJ
Protein Sci; 2017 Oct; 26(10):2021-2038. PubMed ID: 28726352
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal antibody clearance. Impact of modulating the interaction of IgG with the neonatal Fc receptor.
Datta-Mannan A; Witcher DR; Tang Y; Watkins J; Wroblewski VJ
J Biol Chem; 2007 Jan; 282(3):1709-17. PubMed ID: 17135257
[TBL] [Abstract][Full Text] [Related]
17. Diabody-based recombinant formats of humanized IgG-like bispecific antibody with effective retargeting of lymphocytes to tumor cells.
Asano R; Kawaguchi H; Watanabe Y; Nakanishi T; Umetsu M; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
J Immunother; 2008 Oct; 31(8):752-61. PubMed ID: 18779744
[TBL] [Abstract][Full Text] [Related]
18. RUBY® - a tetravalent (2+2) bispecific antibody format with excellent functionality and IgG-like stability, pharmacology and developability properties.
Nyesiga B; Levin M; Säll A; Rosén A; Jansson K; Fritzell S; Hägerbrand K; Weilguny D; von Schantz L
MAbs; 2024; 16(1):2330113. PubMed ID: 38527972
[TBL] [Abstract][Full Text] [Related]
19. Recombinant approaches to IgG-like bispecific antibodies.
Marvin JS; Zhu Z
Acta Pharmacol Sin; 2005 Jun; 26(6):649-58. PubMed ID: 15916729
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of humanized monoclonal anti-tumor necrosis factor-{alpha} antibody and its neonatal Fc receptor variants in mice and cynomolgus monkeys.
Deng R; Loyet KM; Lien S; Iyer S; DeForge LE; Theil FP; Lowman HB; Fielder PJ; Prabhu S
Drug Metab Dispos; 2010 Apr; 38(4):600-5. PubMed ID: 20071453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]